Ranbaxy Laboratories, the leading pharmaceutical firm, has received approval to manufacture and market tamsulosin hydrochloride (TH) capsules in Canada, the company said in a filing to Bombay Stock Exchange today.The company obtained this approval through its wholly-owned subsidiary of the firm, Ranbaxy Pharmaceuticals-Canada Inc. (RPCI) for tamsulosin hydrochloride capsules (0.4mg) from Health Canada, Therapeutic Products Directorate (TPD).This product has proven to be bio-equivalent to Flomax Capsules which is indicated for the treatment of Benign Prostatic Hyperplasia (BPH). Tamsulosin Hydrochloride belongs to group of drugs called Alpha Blockers. It works by blocking alpha receptors in certain areas of the body.RPCI's sales team will be offering Ran-Tamsulosin immediately under the Ranbaxy label in all of the Canadian provinces that now provides another option to pharmacist for this molecule, that will be of benefit to both patients and the Canadian healthcare system.
